Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Abec L


Availability: In stock

Special Price $ 60

BRAND : Abec L
STRENGTH : 600mg + 300mg
INGREDIENT : HIV-AIDS-Emcure-Abacavir-600mg-Lamivudine-300mg-Abec-L
COUNT : 30 Tablets

Description of Abec L

Product details: Trade name: Abec-L Active ingredients: Abacavir and Lamivudine Strength of the ingredients: Abacavir 600mg and Lamivudine 300mg Mfg: Emcure Container: 30 tablets Category: Anti-retroviral agent Abec-L description: Abec-L is a combination tablet that contains ingredients like Abacavir and Lamivudine Abec-L is involved in the treatment of HIV-type I infection, it is used with other anti-retroviral medicines to control the infections. Abec-L is manufactured by Emcure pharma and it is active against HIV viruses which effectively prevent it from progressing to AIDS.

Pharmacology of Abec L

Mechanism of action: Abacavir: Abacavir is a nucleoside reverse transcriptase inhibitor (carboxylic synthetic nucleoside analogue), it has activity against human immunodeficiency virus type I. Abacavir is phosphorylated into an active metabolite carbovir triphosphate (deoxyguanosine 5’triphosphate) dGTP This active metabolite prohibits the action of reverse transcriptase by competing with dGTP and inserted into viral DNA The growth of viral DNA gets affected by insertion of nucleotide which causes lack of OH molecule. OH molecules are essential for the formation of 5’ to 3’ phosphodiester linkage which is responsible for chain elongation. Lamivudine: Lamivudine is one of the ingredients present in Abec- L, it is nucleoside synthetic analogue. Lamivudine is phosphorylated intracellularly into active 5’ triphosphate metabolite (lamivudine triphosphate 3TC-TP. This active metabolite involves in inhibition of reverse transcriptase through chain termination after insertion of nucleotide analogue. Pharmacokinetic: Absorption: After oral administration of tablet Abec- L, abacavir and lamivudine is highly absorbed and its bioavailability occurs at 83% and 87% respectively Distribution: Abec- L is highly bound to human plasma protein nearly 50%; lamivudine has low plasma protein binding. Metabolism: Abacavir metabolism occurred by alcohol dehydrogenase and glucuronyl transferase. Lamivudine is metabolized to trans-sulfoxide and biotransformation is catalyzed by sulfotransferases. Elimination: The terminal half life of abacavir and lamivudine is 1.54±0.63 hours and 5 to 7 hours respectively. Lamivudine is excreted in human milk

Indication of Abec L

Abec- L tablet is indicated for the treatment of HIV type I infection patients. Abec-L should be combined with other anti-retroviral drugs.

Dose & Dosage's of Abec L

The recommended dose of Abec- L tablet is one tablet to be taken orally as a single dose, in combination with other anti-retroviral medicines with or without food. Missed dose: If patient not taken Tablet Abec- L, then the dose should be administered within the time The particular dose should be skipped and continue the next drug schedule

Side Effects of Abec L

Fatal hypersensitivity reactions Lactic acidosis and severe hepatomegaly with steatosis Exacerbations of hepatitis B Hepatic decompensated in patients co-infected with HIV-I and hepatitis C Immune reconstitution syndrome Fat redistribution Myocardial infraction Some common side effects; Insomnia, depression, headache, fatigue, dizziness, rash, pyrexia, abdominal pain, abnormal pain, anxiety

Contraindication of Abec L

Abec- L tablets are contraindicated in the patients having HLA-B 5701 allele Hypersensitivity reaction to components present in the product Severe hepatic impairment

Drug Interaction of Abec L

If taking getting methadone maintenance therapy, with abacavir 600mg twice daily leads to increase the methadone clearance HLA-B*5701 allele not co administered with abacavir due to anaphylactic reactions occurs Ethanol blocks the ability of the kidney to eliminate the drug abacavir Zalcitabine, it is not concomitant with Abec- L because the effect of lamivudine which is present in the drug and Zalcitabine are inhibits each other. Lamivudine and Zalcitabine inhibit intercellular phosphorylation of each other.

Precaution of Abec L

Caution with if patients having; Hypersensitivity reactions, lactic acidosis, severe hepatomegaly with steatosis and exacerbations of hepatitis B Fat redistribution, myocardial infarction, hepatic impairment

Usage & Safety profile of Abec L Pregnancy & Lactation

Pregnancy category: C Abec-L should be used in pregnancy only have potential benefits Abec- L causes birth defects to unborn babies The use of Abec- L in pregnant women may have warrant in use Breastfeeding mothers should not take Abec- L, it excreted in human milk Nursing mothers not give milk to the babies; it might have chance of postnatal transmission.

Storage of Abec L

The storage condition of Abec- L tablets are at room temperature and keep it in dry place It should be keep away from moisture, heat, and light